Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $14.9 million.

  • Monte Rosa Therapeutics' Gains from Investment Securities rose 2891.64% to $14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 2891.64%. This contributed to the annual value of $11.6 million for FY2024, which is 2335.66% up from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Gains from Investment Securities stood at $14.9 million, which was up 2891.64% from $15.2 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Gains from Investment Securities high stood at $15.2 million for Q2 2025, and its period low was -$131000.0 during Q1 2023.
  • Its 3-year average for Gains from Investment Securities is $9.1 million, with a median of $10.7 million in 2023.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 1642.24% in 2024, then soared by 3168.41% in 2025.
  • Over the past 3 years, Monte Rosa Therapeutics' Gains from Investment Securities (Quarter) stood at $9.5 million in 2023, then rose by 22.15% to $11.6 million in 2024, then increased by 28.92% to $14.9 million in 2025.
  • Its Gains from Investment Securities was $14.9 million in Q3 2025, compared to $15.2 million in Q2 2025 and $59000.0 in Q1 2025.